Evidence map›Paper›PMID 39863723›Full record

ArticleScientific reports2025

Development and characterization of in vitro inducible immortalization of a murine microglia cell line for high throughput studies.

Hana Yeh, Matthew A De Cruz, Yang You, Seiko Ikezu, Tsuneya Ikezu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hana YehGraduate Program in Neuroscience, Boston University, Boston, United States.
Matthew A De CruzDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.
Yang YouDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, United States.
Seiko IkezuDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, United States.
Tsuneya IkezuDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, United States. Ikezu.tsuneya@mayo.edu.

Funding

Molecular characterization of extracellular vesicles for the spread of misfolded tau proteinR01AG067763 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$3.1M
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse modelR01AG072719 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2021 to 2025
$2.7M
Therapeutic evaluation of targeting Tau Tubulin kinase-1 in Alzheimer’s diseaseR01AG079859 · NIA · MAYO CLINIC JACKSONVILLE · PI Seiko Ikezu · 2023 to 2026
$2.2M
Tumor susceptibility gene 101, a new microglial therapy candidate for Alzheimer’s disease to prevent cognitive declineRF1AG082704 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, SEIKO, IKEZU, TSUNEYA · 2023 to 2023
$2.0M
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's diseaseR01AG066429 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2020 to 2024
$2.0M
APOE and microglia-mediated progression in tau pathology in ADR01AG054199 · NIA · MAYO CLINIC JACKSONVILLE · PI IKEZU, TSUNEYA · 2024 to 2025
$1.4M
NIA NIH HHS R01 AG054199NIA NIH HHS R01 AG066429NIA NIH HHS R01 AG066429, R01 AG067763, R01 AG072719, R01 AG054199, RF1 AG082704, R01 AG079859NIA NIH HHS R01 AG067763NIA NIH HHS R01 AG072719NIA NIH HHS R01 AG079859NIA NIH HHS RF1 AG082704NIA NIH HHS RF1 AG082704, R01 AG079859
6 · The paper itself

Abstract

There are few in vitro models available to study microglial physiology in a homeostatic context. Recent approaches include the human induced pluripotent stem cell model, but these can be challenging for large-scale assays and may lead to batch variability. To advance our understanding of microglial biology while enabling scalability for high-throughput assays, we developed an inducible immortalized murine microglial cell line using a tetracycline expression system. The addition of doxycycline facilitates rapid cell proliferation, allowing for population expansion. Upon withdrawal of doxycycline, this monoclonal microglial cell line differentiates, resembling in vivo microglial physiology as demonstrated by the expression of microglial genes, innate immune responses, chemotaxis, and phagocytic abilities. We utilized live imaging and various molecular techniques to functionally characterize the clonal 2E11murine microglial cell line. Transcriptomic analysis showed that the 2E11 line exhibited characteristics of immature, proliferative microglia during doxycycline induction, and further differentiation led to a more homeostatic phenotype. Treatment with transforming growth factor-β modified the transcriptome of the 2E11 cell line, affecting cellular immune pathways. Our findings indicate that the 2E11 inducible immortalized cell line is a practical and convenient tool for studying microglial biology in vitro.

Indexed as

High-Throughput Screening AssaysMicrogliaAnimalsCell DifferentiationCell LineCell Line, TransformedCell ProliferationDoxycyclineGene Expression ProfilingMiceTranscriptomeTransforming Growth Factor betaDoxycyclineTransforming Growth Factor betaChemotaxisCytokinesInducible immortalized cell lineMurine microgliaPhagocytosisTranscriptomics

Identifiers

PMID39863723
PMCPMC11762310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.